These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30739116)

  • 21. Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young.
    De Brabander I; Yperzeele L; Ceuterick-De Groote C; Brouns R; Baker R; Belachew S; Delbecq J; De Keulenaer G; Dethy S; Eyskens F; Fumal A; Hemelsoet D; Hughes D; Jeangette S; Nuytten D; Redondo P; Sadzot B; Sindic C; Sheorajpanday R; Thijs V; Van Broeckhoven C; De Deyn PP
    Clin Neurol Neurosurg; 2013 Jul; 115(7):1088-93. PubMed ID: 23219219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of Fabry disease among Turkish dialysis patients: Data from hemodialysis centers in Bursa province.
    Sayilar EI; Ayar Y; Yavuz M
    Clin Nephrol; 2016 Mar; 85(3):165-72. PubMed ID: 26833297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two-tier approach for the detection of alpha-galactosidase A deficiency in kidney transplant recipients.
    De Schoenmakere G; Poppe B; Wuyts B; Claes K; Cassiman D; Maes B; Verbeelen D; Vanholder R; Kuypers DR; Lameire N; De Paepe A; Terryn W
    Nephrol Dial Transplant; 2008 Dec; 23(12):4044-8. PubMed ID: 18596132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of Fabry's disease within hemodialysis patients in Spain.
    Herrera J; Miranda CS
    Clin Nephrol; 2014 Feb; 81(2):112-20. PubMed ID: 24365053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fabry disease in patients with end-stage renal failure: the potential benefits of screening.
    Bekri S; Enica A; Ghafari T; Plaza G; Champenois I; Choukroun G; Unwin R; Jaeger P
    Nephron Clin Pract; 2005; 101(1):c33-8. PubMed ID: 15886492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fabry disease screening in high-risk populations in Japan: a nationwide study.
    Yoshida S; Kido J; Sawada T; Momosaki K; Sugawara K; Matsumoto S; Endo F; Nakamura K
    Orphanet J Rare Dis; 2020 Aug; 15(1):220. PubMed ID: 32843101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Frequency of Fabry Disease in Patients with Cardiac Hypertrophy of Various Phenotypes Including Prominent Papillary Muscle: The TUCARFAB Study in Turkey.
    Özpelit E; Çavuşoğlu Y; Yorgun H; Ökçün EÖB; Eker Akıllı R; Çelik A; Ermiş N; Gerede Uludağ DM; Kahveci G; Uslu Çil Ş; Erfidan E; Tufekcioglu O
    Anatol J Cardiol; 2023 Apr; 27(4):223-228. PubMed ID: 36995061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel α-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease.
    Duro G; Musumeci MB; Colomba P; Zizzo C; Albeggiani G; Mastromarino V; Volpe M; Autore C
    Gene; 2014 Feb; 535(2):365-9. PubMed ID: 24140492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients.
    Kotanko P; Kramar R; Devrnja D; Paschke E; Voigtländer T; Auinger M; Pagliardini S; Spada M; Demmelbauer K; Lorenz M; Hauser AC; Kofler HJ; Lhotta K; Neyer U; Pronai W; Wallner M; Wieser C; Wiesholzer M; Zodl H; Födinger M; Sunder-Plassmann G
    J Am Soc Nephrol; 2004 May; 15(5):1323-9. PubMed ID: 15100373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of the alpha galactosidase gene: mutation profile and description of two novel mutations with extensive literature review in Turkish population.
    Onay H; Bolat H; Kılıç Yıldırım G; Kose E; Kalkan Uçar S; Aşıkovalı S; Özkınay F; Çoker M
    J Pediatr Endocrinol Metab; 2020 Aug; 33(10):1245-1250. PubMed ID: 32813676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anderson-Fabry disease: a case-finding study among male kidney transplant recipients in Austria.
    Kleinert J; Kotanko P; Spada M; Pagliardini S; Paschke E; Paul K; Voigtländer T; Wallner M; Kramar R; Stummvoll HK; Schwarz C; Horn S; Holzer H; Födinger M; Sunder-Plassmann G
    Transpl Int; 2009 Mar; 22(3):287-92. PubMed ID: 18954370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of Fabry Disease in patients with left ventricular hypertrophy in Turkey: Multicenter study (LVH-TR subgroup analysis).
    Güzel T; Çağlar FNT; Ekici B; Kış M; Öztaş S; Öz A; Gök G; Kolak Z; Akşit E; Sarıca SA; Bayrak M; Birdal O; Uğuz B; Gitmez M; Berk Gİ; Oğuz M; Çalık AN; Kılıç S; Zoghi M; Ergene AO
    Int J Cardiovasc Imaging; 2023 Jun; 39(6):1143-1155. PubMed ID: 36920623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic Screening of Anderson-Fabry Disease in Probands Referred From Multispecialty Clinics.
    Favalli V; Disabella E; Molinaro M; Tagliani M; Scarabotto A; Serio A; Grasso M; Narula N; Giorgianni C; Caspani C; Concardi M; Agozzino M; Giordano C; Smirnova A; Kodama T; Giuliani L; Antoniazzi E; Borroni RG; Vassallo C; Mangione F; Scelsi L; Ghio S; Pellegrini C; Zedde M; Fancellu L; Sechi G; Ganau A; Piga S; Colucci A; Concolino D; Di Mascio MT; Toni D; Diomedi M; Rapezzi C; Biagini E; Marini M; Rasura M; Melis M; Nucera A; Guidetti D; Mancuso M; Scoditti U; Cassini P; Narula J; Tavazzi L; Arbustini E
    J Am Coll Cardiol; 2016 Sep; 68(10):1037-50. PubMed ID: 27585509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.
    Nakao S; Kodama C; Takenaka T; Tanaka A; Yasumoto Y; Yoshida A; Kanzaki T; Enriquez AL; Eng CM; Tanaka H; Tei C; Desnick RJ
    Kidney Int; 2003 Sep; 64(3):801-7. PubMed ID: 12911529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance.
    van der Tol L; Smid BE; Poorthuis BJ; Biegstraaten M; Deprez RH; Linthorst GE; Hollak CE
    J Med Genet; 2014 Jan; 51(1):1-9. PubMed ID: 23922385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for Fabry disease in left ventricular hypertrophy: documentation of a novel mutation.
    Baptista A; Magalhães P; Leão S; Carvalho S; Mateus P; Moreira I
    Arq Bras Cardiol; 2015 Aug; 105(2):139-44. PubMed ID: 26269958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Frequency of Fabry Disease among Young Cryptogenic Stroke Patients in the City of Sakarya.
    Gündoğdu AA; Kotan D; Alemdar M
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1334-1340. PubMed ID: 28283366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study.
    Inoue T; Hattori K; Ihara K; Ishii A; Nakamura K; Hirose S
    J Hum Genet; 2013 Aug; 58(8):548-52. PubMed ID: 23677059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening of Fabry disease in patients with chronic kidney disease in Japan.
    Nagata A; Nasu M; Kaida Y; Nakayama Y; Kurokawa Y; Nakamura N; Shibata R; Hazama T; Tsukimura T; Togawa T; Saito S; Sakuraba H; Fukami K
    Nephrol Dial Transplant; 2021 Dec; 37(1):115-125. PubMed ID: 34282462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Fabry's disease (alpha-galactosidase-A deficiency): physiopathology, clinical signs, and genetic aspects].
    Germain DP
    J Soc Biol; 2002; 196(2):161-73. PubMed ID: 12360745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.